For the third quarter of 2026, analysts expect Collegium Pharmaceutical to report consensus revenue of approximately $216.03 million and adjusted EPS of $1.86, with the current stock price of $24.28 trading significantly below the $49.00 average analyst target.
Investors are primarily focused on the commercial performance of Jornay PM, the leading ADHD medication acquired through the 2024 Ironshore Therapeutics deal, as it now serves as the company's primary growth engine.
While the legacy pain management portfolio remains a foundational cash generator, management's ability to drive expansion in the neuropsychiatry market is critical for long-term revenue diversification. Analysts will also be looking for updates on the integration of recent asset acquisitions and potential revisions to full-year 2026 guidance.